Banyan Capital Management Inc. Takes Position in Eli Lilly and Company $LLY

Banyan Capital Management Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 750 shares of the company’s stock, valued at approximately $572,000.

Several other institutional investors also recently bought and sold shares of LLY. Lazard Freres Gestion S.A.S. grew its position in Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Exencial Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after buying an additional 11,396 shares in the last quarter. Rede Wealth LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth approximately $487,000. Precedent Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares during the last quarter. Finally, Central Pacific Bank Trust Division grew its holdings in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after buying an additional 1,843 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.0%

Shares of NYSE:LLY opened at $1,023.81 on Friday. The stock’s 50-day simple moving average is $1,057.27 and its two-hundred day simple moving average is $887.02. The stock has a market capitalization of $967.89 billion, a price-to-earnings ratio of 50.09, a PEG ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Ratings Changes

Several equities analysts recently issued reports on LLY shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $1,173.91.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a potential $1.93 billion deal with Repertoire Immune Medicines to develop autoimmune therapies, expanding its pipeline in high?value immune diseases and adding near? and mid?term development optionality. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Lilly agreed to a collaboration/option deal with gene?editing firm Seamless (up to $1.12B) targeting hearing?loss programs—diversifies R&D and signals commitment to next?gen modalities. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — a boost for supply-chain resilience, potential capacity for GLP?1 and other biologics, and a politically favorable narrative. Trump says Eli Lilly to build six US plants
• Positive Sentiment: Analysts/coverage point to strong Q4 fundamentals, oncology pipeline momentum and an AI partnership (Nvidia) positioning Lilly for R&D acceleration—supportive for earnings and longer?term growth expectations. Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Positive Sentiment: A Seeking Alpha take argues Lilly’s obesity?pricing tradeoffs (access vs. price) are a net positive, supporting adoption and sales momentum for GLP?1/obesity launches. Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
• Neutral Sentiment: Wall Street expects continued earnings strength and a likely beat in the upcoming report based on Lilly’s recent surprise history—this can support sentiment if results meet/beat. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Coverage pieces and bullish theses reiterate Lilly’s secular GLP?1/oncology story but note valuation is rich—supports conviction but increases sensitivity to execution. Eli Lilly and Company (LLY): A Bull Case Theory
• Negative Sentiment: Competitive pressure: Novo Nordisk is outspending Lilly on U.S. GLP?1 advertising by a wide margin, which could pressure market share and marketing efficiency. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Policy risk: Medicare’s expanded negotiation list includes Lilly’s Verzenio, introducing potential pricing pressure for certain oncology revenues if negotiations lead to cuts. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Market reaction: some coverage notes shares dipped after the gene?editing tie?up, illustrating sensitivity to deal economics and investor focus on near?term margins versus long?term optionality. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.